Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Enzo Biochem (ENZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 486,495
  • Shares Outstanding, K 46,510
  • Annual Sales, $ 102,770 K
  • Annual Income, $ 45,290 K
  • 36-Month Beta 0.92
  • Price/Sales 4.57
  • Price/Cash Flow N/A
  • Price/Book 5.47

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.35 +0.97%
on 09/18/17
11.50 -9.13%
on 09/05/17
-0.49 (-4.48%)
since 08/22/17
3-Month
10.35 +0.97%
on 09/18/17
12.04 -13.21%
on 07/14/17
-0.57 (-5.17%)
since 06/22/17
52-Week
4.88 +114.14%
on 09/30/16
12.04 -13.21%
on 07/14/17
+5.25 (+100.96%)
since 09/22/16

Most Recent Stories

More News
Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter 2017 Results Thursday September 28, 2017 at 8:30 AM E.T.

Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2017 fourth quarter results Thursday, September 28, 2017, at 8:30 AM E.T.

ENZ : 10.45 (-0.10%)
Aeon Global Health, Operating Arm of Authentidate Holding Corp., Names David C. Goldberg as its new Chief Operating Officer

Authentidate Holding Corp. (OTCQB:ADAT), a growth oriented company focused on developing and providing clinically actionable medical information and telemedicine services, announced today that David C....

ENZ : 10.45 (-0.10%)
ADAT : 1.6500 (+5.77%)
Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern

Geron Corporation's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.

ENZ : 10.45 (-0.10%)
GERN : 2.16 (-0.92%)
ACAD : 37.59 (-0.11%)
ADRO : 10.80 (-1.82%)
Pacira Pharmaceuticals Focuses on Exparel's Label Expansion

Pacira Pharmaceuticals, Inc. (PCRX) is making efforts to expand its flagship product, Exparel, which was launched in 2012.

ENZ : 10.45 (-0.10%)
JNJ : 131.39 (-0.27%)
PCRX : 37.20 (+2.06%)
SNY : 50.34 (+0.78%)
Nektar's (NKTR) Shares Fall Post Wider Q2 Loss, Revenues Lag

Nektar (NKTR) reports wider-than-expected loss with revenues falling shy of estimates. However, the top line rises year over year, courtesy an increase in product sales and royalty revenues.

ENZ : 10.45 (-0.10%)
LLY : 83.91 (+0.70%)
BMY : 63.36 (+0.05%)
NKTR : 22.43 (+2.56%)
Novo Nordisk (NVO) Beats on Q2 Earnings, Revenues Miss

Novo Nordisk A/S (NVO) beat earnings estimates but missed revenue estimates in Q2. Robust performance for Victoza and Tresiba will drive growth.

ENZ : 10.45 (-0.10%)
NVO : 49.22 (+0.33%)
ADRO : 10.80 (-1.82%)
SNY : 50.34 (+0.78%)
Intrexon (XON) Q2 Loss Narrower than Expected, Revenues Miss

Intrexon Corporation (XON) incurred narrower than expected loss and missed revenue estimates in Q2.

ENZ : 10.45 (-0.10%)
XON : 18.75 (unch)
ZIOP : 6.17 (+1.82%)
SNY : 50.34 (+0.78%)
Catalyst (CPRX) Posts Narrower than Expected Loss in Q2

Catalyst Pharmaceuticals, Inc. (CPRX) reported narrower than expected loss in Q2 and is focused on the development of its pipeline candidate Firdapse.

ENZ : 10.45 (-0.10%)
CPRX : 2.44 (unch)
ADRO : 10.80 (-1.82%)
SNY : 50.34 (+0.78%)
Perrigo (PRGO) Q2 Earnings & Sales Top, 2017 View Raised

Perrigo (PRGO) posts better-than-expected results with revenue beating estimates. The company also ups its earnings outlook, courtesy a continued positive execution across all business segments.

ENZ : 10.45 (-0.10%)
SMMT : 12.68 (+0.36%)
ADRO : 10.80 (-1.82%)
PRGO : 84.93 (-0.13%)
The Medicines Company (MDCO) Q2 Loss Widens, Revenues Miss

The Medicines Company (MDCO) reports wider-than-expected loss with revenues missing estimates. The top line also decreases year over year due to low Angiomax sales.

ENZ : 10.45 (-0.10%)
MDCO : 35.44 (+1.40%)
ALNY : 113.80 (+0.78%)
NVS : 86.16 (+1.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo...

See More

Support & Resistance

2nd Resistance Point 10.68
1st Resistance Point 10.57
Last Price 10.45
1st Support Level 10.37
2nd Support Level 10.28

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.